News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,228 Results
Type
Article (41606)
Company Profile (463)
Press Release (659159)
Section
Business (208412)
Career Advice (2005)
Deals (35944)
Drug Delivery (92)
Drug Development (83303)
Employer Resources (169)
FDA (16325)
Job Trends (15046)
News (352108)
Policy (32982)
Tag
Academia (2619)
Alliances (50616)
Alzheimer's disease (1274)
Approvals (16252)
Artificial intelligence (139)
Bankruptcy (361)
Best Places to Work (11733)
Biotechnology (349)
Breast cancer (124)
Cancer (1120)
Cardiovascular disease (102)
Career advice (1673)
Cell therapy (250)
Clinical research (66008)
Collaboration (409)
Compensation (202)
COVID-19 (2590)
C-suite (100)
Data (1145)
Diabetes (156)
Diagnostics (6198)
Earnings (86048)
Employer resources (147)
Events (112941)
Executive appointments (316)
FDA (16874)
Funding (369)
Gene therapy (194)
GLP-1 (612)
Government (4410)
Healthcare (18996)
Infectious disease (2675)
Inflammatory bowel disease (113)
Interviews (308)
IPO (16573)
Job creations (3695)
Job search strategy (1429)
Layoffs (439)
Legal (7928)
Lung cancer (174)
Manufacturing (181)
Medical device (13324)
Medtech (13329)
Mergers & acquisitions (19435)
Metabolic disorders (426)
Neuroscience (1565)
NextGen Class of 2024 (6733)
Non-profit (4533)
Northern California (1500)
Obesity (245)
Opinion (198)
Patents (103)
People (57639)
Phase I (20686)
Phase II (29142)
Phase III (21547)
Pipeline (462)
Postmarket research (2590)
Preclinical (8885)
Radiopharmaceuticals (252)
Rare diseases (235)
Real estate (5998)
Regulatory (21964)
Research institute (2404)
Resumes & cover letters (351)
Southern California (1327)
Startups (3747)
United States (13902)
Vaccines (565)
Weight loss (183)
Date
Today (132)
Last 7 days (716)
Last 30 days (3808)
Last 365 days (36739)
2024 (33722)
2023 (41013)
2022 (52276)
2021 (56765)
2020 (54924)
2019 (47420)
2018 (35698)
2017 (33033)
2016 (32350)
2015 (38406)
2014 (32189)
2013 (27124)
2012 (29226)
2011 (29868)
2010 (27999)
Location
Africa (731)
Arizona (200)
Asia (38518)
Australia (6404)
California (3425)
Canada (1300)
China (254)
Colorado (150)
Connecticut (162)
Europe (84002)
Florida (464)
Georgia (116)
Illinois (354)
Indiana (199)
Kansas (99)
Maryland (590)
Massachusetts (2732)
Michigan (159)
Minnesota (279)
New Jersey (972)
New York (977)
North Carolina (759)
Northern California (1500)
Ohio (141)
Pennsylvania (853)
South America (1105)
Southern California (1327)
Texas (478)
Utah (92)
Washington State (375)
701,228 Results for "allay therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan
Allay Therapeutics, Inc. (Allay) today announced that they have entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (Maruishi), providing Maruishi with exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, and other ultra-sustained analgesic implantable drug candidates for acute pain in Japan.
December 18, 2023
·
4 min read
Press Releases
Allay Therapeutics Announces Expansion of Clinical and Scientific Advisory Boards to Support the Company’s Mission to Transform Post-Surgical Pain Management
October 24, 2024
·
12 min read
Drug Development
Allay Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application to Initiate Pivotal Phase 2B Trial of ATX101 for the Treatment of Post-Surgical Pain Following Total Knee Replacement Surgery
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced plans to proceed to a Phase 2b registration trial of its lead investigational product ATX101.
June 12, 2024
·
4 min read
Drug Development
Allay Therapeutics’ Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced the results from a Phase 2B clinical study of its lead investigational product ATX101.
April 11, 2024
·
7 min read
Business
Allay Therapeutics Appoints Nicole Vitullo to Board of Directors
Allay Therapeutics announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.
September 6, 2023
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Versant Ventures Unveils Pep2Tango Therapeutics Inc.
November 21, 2024
·
4 min read
Press Releases
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
November 13, 2024
·
4 min read
Business
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.
June 27, 2024
·
5 min read
Press Releases
ReCerise Therapeutics Inc. Selected for Government Project by MOTIE
Initiates Development of Tailored Innovative Targeted Therapy for Refractory Cancer ReCerise Therapeutics Inc., has announced its selection for a grant from the Ministry of Trade, Industry and Energy of South Korea.
July 1, 2024
·
2 min read
1 of 70,123
Next
